Here, the authors identify a LYPD3+/TACSTD2+/LY6D+ BCC subpopulation of resistant BCC cells where AP-1 and TGFß drive nMRTF activation and amplify noncanonical Gli1 activity. This evidence concerns the gene LY6D and skin basal cell carcinoma.